⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SCNI News
Scinai Immunotherapeutics Ltd. American Depositary Shares
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
prnewswire.com
SCNI
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
prnewswire.com
SCNI
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
prnewswire.com
SCNI
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
prnewswire.com
SCNI
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
prnewswire.com
SCNI
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
prnewswire.com
SCNI
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
prnewswire.com
SCNI
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
prnewswire.com
SCNI
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
prnewswire.com
SCNI
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
prnewswire.com
SCNI